Evidence map›Paper›PMID 39648976›Full record

ReviewJournal of medical radiation sciences2025

Quantifying non-clinical outcomes of ultra-hypofractionated breast radiotherapy in Western NSW-A narrative review.

Faith Yeo, Rachael Beldham-Collins, Paul Roth, Rodney Hammond

Abstract readReview
In one paragraph

Review in Journal of medical radiation sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Faith YeoSydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.ORCID https://orcid.org/0009-0008-2592-0264
Rachael Beldham-CollinsCentral West Cancer Centre, Orange Health Service, Orange, New South Wales, Australia.ORCID https://orcid.org/0000-0002-0040-4772
Paul RothSchool of Rural Health, Faculty of Medicine and Health, University of Sydney, 4 Moran Drive, Dubbo, 2830, New South Wales, Australia.ORCID https://orcid.org/0009-0008-9340-1917
Rodney HammondCentral West Cancer Centre, Orange Health Service, Orange, New South Wales, Australia.ORCID https://orcid.org/0000-0002-2987-521X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ultra-Hypofractionated Whole Breast Radiotherapy (U-WBRT) has been proven to be a viable treatment option for breast cancer patients receiving radiation therapy, however, due to its novelty our understanding of its non-clinical benefits is still evolving. With increasing U-WBRT selection during COVID and in rural and regional settings such as the Western New South Wales Local Health District (WNSWLHD), it's important to quantify the savings when compared to other fractionation schedules (e.g. Conventional fractionation (C-WBRT) involving 25 fractions and Moderate hypofractionation (M-WBRT) with 15 fractions.) Using literature sourced from Medline, Embase, Pubmed and reports from relevant websites and organisations this narrative review investigates quantifiable methods of assessing non-clinical benefits of U-WBRT in rural settings according to the triple bottom line philosophy. This review was able to identify a standard set of quantifiable metrics that can compare the non-clinical benefits of various fractionation schedules, with relevance to a rural setting. These include: fractionation trends, financial subsidy, average linear accelerator (Linac) minutes, hospital visits, travel time and distance, Linac energy consumption, travel and Linac carbon emissions. By identifying these metrics, non-clinical benefits between the fractionation schedules can easily be quantified and compared.

Indexed as

Breast NeoplasmsRadiation Dose HypofractionationCOVID-19FemaleHumansNew South WalesTreatment OutcomeBreast cancernon‐clinical benefitsruraltriple bottom lineultra‐hypofractionated radiotherapy

Identifiers

PMID39648976
PMCPMC12449613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.